Current Report Filing (8-k)
08 June 2021 - 6:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or Section 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
June 7, 2021
DARIOHEALTH CORP.
(Exact name of registrant as specified in its charter)
Delaware
|
|
001-37704
|
|
45-2973162
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
142 W. 57th St., 8th Floor
New York, New York 10019
(Address of Principal
Executive Offices)
(646) 665-4667
(Issuer’s telephone
number)
(Former name or former
address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of exchange on which
registered
|
Common Stock, par value $0.0001 per share
|
|
DRIO
|
|
The Nasdaq Capital Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
Adoption of an amendment to the 2020 Equity Incentive Plan
On June 7, 2021, DarioHealth Corp. (the “Company”) held
its 2021 Annual Meeting of Stockholders (the “2021 Annual Meeting”). At the 2021 Annual Meeting, the Company’s
stockholders approved an amendment to the Company's 2020 Equity Incentive Plan (the “2020 Plan”) to increase the number
of shares authorized for issuance under the 2020 Plan by 700,000 shares from 1,828,890 to 2,528,890 (the “Plan Amendment”).
The Plan Amendment was previously approved, subject to stockholder approval, by the Company’s Board of Directors (the “Board”),
upon the recommendation of the Board’s Compensation Committee on April 15, 2021.
A detailed summary of the Plan Amendment
is set forth in the Company’s Definitive Proxy Statement on Schedule 14A for the 2021 Annual Meeting filed with the Securities
and Exchange Commission on April 26, 2021 (the “Proxy Statement”) under the caption “Proposal 2: Incentive Plan
Proposal,” which summary is incorporated herein by reference.
That detailed summary of the Plan Amendment is
qualified in its entirety by reference to the full text of the Plan Amendment, a copy of which is attached as Annex A to the Company’s
Proxy Statement, and is incorporated herein by reference.
Item 5.07.
|
Submission of Matters to a Vote of Security Holders.
|
The final voting results of the 2021 Annual Meeting
held on June 7, 2021, are set forth below. Stockholders voted on the following proposals:
Proposal No. 1 — Election of Directors.
The stockholders elected the following directors
of the Company to hold office until the next annual meeting of stockholders and until their respective successors shall be elected and
qualified or until their earlier resignation or removal. The votes were as follows (including shares of preferred stock eligible to vote,
on an as converted basis):
Director Name
|
|
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
Hila Karah
|
|
7,486,849
|
|
128,643
|
|
65,972
|
|
2,182,524
|
|
|
|
|
|
|
|
|
|
Dennis Matheis
|
|
7,606,391
|
|
9,050
|
|
66,023
|
|
2,182,524
|
|
|
|
|
|
|
|
|
|
Dennis M. McGrath
|
|
7,400,761
|
|
214,685
|
|
66,018
|
|
2,182,524
|
|
|
|
|
|
|
|
|
|
Erez Raphael
|
|
7,604,911
|
|
10,580
|
|
65,973
|
|
2,193,104
|
|
|
|
|
|
|
|
|
|
Yoav Shaked
|
|
7,400,553
|
|
214,938
|
|
65,973
|
|
2,182,524
|
|
|
|
|
|
|
|
|
|
Adam K. Stern
|
|
7,597,068
|
|
18,423
|
|
65,973
|
|
2,182,524
|
|
|
|
|
|
|
|
|
|
Richard B. Stone
|
|
7,502,397
|
|
119,369
|
|
65,873
|
|
2,176,349
|
Proposal No. 2 — Incentive Plan Proposal.
The stockholders approved the Plan Amendment.
The Plan Amendment proposal required the affirmative vote of a majority of the votes cast at the 2021 Annual Meeting. The votes were as
follows (including shares of preferred stock eligible to vote, on an as converted basis):
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
5,510,502
|
|
2,114,088
|
|
56,874
|
|
2,182,524
|
Proposal No. 3 — Amendment To Certificate Of Incorporation
Proposal.
The stockholders did not approve the amendment to the certificate of
incorporation of the Company. The votes were as follows (including shares of preferred stock eligible to vote, on an as converted basis):
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
5,609,591
|
|
2,059,826
|
|
12,047
|
|
2,182,524
|
Proposal No. 4 — Amendment To Bylaws Proposal.
The stockholders did not approve the amendment to the Company’s
bylaws. The votes were as follows (including shares of preferred stock eligible to vote, on an as converted basis):
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
7,566,889
|
|
76,824
|
|
37,751
|
|
2,182,524
|
Proposal No. 5 — Ratification of Auditors.
The stockholders ratified the appointment of Kost
Forer Gabbay& Kasierer, a member of Ernst & Young Global, as the independent registered public accounting firm of the Company
for the fiscal year ending December 31, 2021. The votes were as follows (including shares of preferred stock eligible to vote, on an as
converted basis):
For
|
|
Against
|
|
Abstain
|
9,732,605
|
|
93,817
|
|
37,566
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: June 7, 2021
|
DARIOHEALTH CORP.
|
|
|
|
|
|
By:
|
/s/ Zvi Ben David
|
|
|
Name: Zvi Ben David
Title: Chief Financial Officer, Treasurer and Secretary
|
DarioHealth (NASDAQ:DRIO)
Historical Stock Chart
From Apr 2024 to May 2024
DarioHealth (NASDAQ:DRIO)
Historical Stock Chart
From May 2023 to May 2024